Gilead Sciences (GILD) Liabilities and Shareholders Equity (2009 - 2026)

Gilead Sciences (GILD) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $56.3 billion the latest figure, recorded in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $56.3 billion, changed 0.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $229.6 billion (up 2.69% YoY), and the FY2025 annual result was $59.0 billion, changed 0.05% from the prior year.
• Liabilities and Shareholders Equity was $56.3 billion for Q1 2026 at Gilead Sciences, down from $59.0 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $63.2 billion in Q4 2022 and troughed at $53.6 billion in Q2 2024.
• Average Liabilities and Shareholders Equity over 5 years is $59.4 billion, with a median of $59.0 billion recorded in 2025.
• Year-over-year, Liabilities and Shareholders Equity retreated 14.05% in 2024 and grew 7.35% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $63.2 billion in 2022, then slipped by 1.66% to $62.1 billion in 2023, then retreated by 5.04% to $59.0 billion in 2024, then rose by 0.05% to $59.0 billion in 2025, then decreased by 4.65% to $56.3 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $56.3 billion in Q1 2026, $59.0 billion in Q4 2025, and $58.5 billion in Q3 2025.